Cirincione, Ann https://orcid.org/0000-0003-0475-5331
Simpson, Danny https://orcid.org/0000-0001-9690-3527
Yan, Weihao https://orcid.org/0009-0000-2509-1816
McNulty, Ryan https://orcid.org/0000-0001-6727-7408
Ravisankar, Purnima https://orcid.org/0000-0001-7799-4558
Solley, Sabrina C. https://orcid.org/0000-0002-2356-5608
Yan, Jun https://orcid.org/0009-0005-9139-3966
Lim, Fabian https://orcid.org/0000-0001-5628-7707
Farley, Emma K. https://orcid.org/0000-0002-9241-247X
Singh, Mona
Adamson, Britt https://orcid.org/0000-0002-9451-5819
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM138167, RM1HG009490, P30CA072720, T32HG003284, T32HG003284, T32HG003284, T32GM007388, F31HD113443, R01-GM076275)
Eric and Wendy Schmidt Transformative Technology Fund Princeton University Searle Scholars Program
National Science Foundation (DGE-2039656, 2239957)
New Jersey Commission on Cancer Research (NJCCR) under award number COCR24PRF021
J.Y. was supported by a fellowship provided by the China Scholarship Council (CSC), based on the April 2015 Memorandum of Understanding between the CSC and Princeton University.
Article History
Received: 12 March 2024
Accepted: 11 October 2024
First Online: 19 November 2024
Competing interests
: B.A. is an advisory board member with options for Arbor Biotechnologies and Tessera Therapeutics. B.A. holds equity in Celsius Therapeutics. J.Y. and B.A. have filed patent application(s) on prime editing technologies. The remaining authors declare no competing interests.